Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 5/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 11/20 | 0.34 |
| ▸ | EP300 | Q09472 | 10/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17229622 | 0.85 | MAPK1 (0.48) | MAPK1RBP4CREBBPEP300BRD4 | |
| SCHEMBL28662073 | 0.82 | CREBBP (0.39) | MAPK1RBP4CYP2C19CREBBPEP300 | |
| SCHEMBL17229709 | 0.81 | RBP4 (0.44) | MAPK1RBP4CREBBPEP300BRD4 | |
| SCHEMBL17229740 | 0.80 | MAPK1 (0.36) | MAPK1RBP4CYP2C19CREBBPEP300 | |
| SCHEMBL17229850 | 0.79 | RBP4 (0.44) | RBP4CREBBPEP300BRD4 | |
| SCHEMBL17229734 | 0.79 | RBP4 (0.43) | MAPK1RBP4CREBBPEP300BRD4 | |
| SCHEMBL17229729 | 0.79 | RBP4 (0.39) | MAPK1RBP4CREBBPEP300BRD4 | |
| SCHEMBL17229691 | 0.79 | CREBBP (0.53) | MAPK1RBP4CREBBPEP300BRD4 | |
| SCHEMBL17229710 | 0.78 | RBP4 (0.46) | MAPK1RBP4CREBBPEP300BRD4 | |
| SCHEMBL17229724 | 0.77 | CGAS (0.42) | MAPK1RBP4CREBBPEP300BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030060-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030060-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HRH4, HRH3, HRH2 | MAPK1 2271/4885RBP4 1884/4885CYP2C19 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.